Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults

World Journal of Biological Psychiatry

Volumn 15, Issue 5, 2014, Pages 404-410

  Garfield, Lauren D ^a   Müller, Daniel J ^b   Kennedy, James L ^b   Mulsant, Benoit H ^b   Reynolds III, Charles F ^c,d   Teitelbaum, Steven L ^a   Civitelli, Roberto ^a   Dixon, David ^a   Todorov, Alexandre A ^a   Lenze, Eric J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aged; Biological markers; Bone diseases; Pharmacogenetics; Serotonin

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; SEROTONIN 1B RECEPTOR; SEROTONIN TRANSPORTER; VENLAFAXINE; CYCLOHEXANOL DERIVATIVE; HTR1B PROTEIN, HUMAN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BONE METABOLISM; CLINICAL TRIAL; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OSSIFICATION; OSTEOLYSIS; PREDICTION; PROMOTER REGION; AGED; BLOOD; BONE DEVELOPMENT; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; GENETIC VARIATION; GENETICS; MIDDLE AGED;

AGED; BONE RESORPTION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; OSTEOGENESIS; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; VENLAFAXINE HYDROCHLORIDE;

EID: 84904340424     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2013.832380     Document Type: Article

References (47)

1. Battaglino R, Vokes M, Schulze-Spate U, Sharma A, Graves D, Kohler T, et al. 2007. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem 100:1387-1394
2. Beevers CG, Marti CN, Lee HJ, Stote DL, Ferrell RE, Hariri AR, Telch MJ. 2011. Associations between serotonin transporter gene promoter region (5-HTTLPR) polymorphism and gaze bias for emotional information. J Abnorm Psychol 120:187-197
3. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 356:1809-1822
4. Bliziotes M. 2010. Update in serotonin and bone. J Clin Endocrinol Metab 95:4124-4132
5. Bliziotes M, Eshleman A, Burt-Pichat B, Zhang XW, Hashimoto J, Wiren K, Chenu C. 2006. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39:1313-1321
6. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren KM. 2001 Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake. Bone 29:477-486
7. Calarge CA, Ellingrod VL, Zimmerman B, Bliziotes MM, Schlechte JA. 2011. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-Treated boys: A reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin psychiatry 72:1685-1690
8. Civitelli R, Aramamento-Villareal R, Napoli N. 2009. Bone turnover markers: Understanding their value in clinical trials and clinical practice. Osteoporo Int 20:843-851
9. Collet C, Schiltz C, Geoffroy V, Maroteaux L, Launay JM, De Vernejoul MC. 2008. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 22:418-427
10. Conner TS, Jensen KP, Tennen H, Furneaux HM, Kranzler HR, Covault J. 2010. Functional polymorphisms in the serotonin 1B receptor gene (HTR1B) predict self-reported anger and hostility amoong young men. Am J Med Genet B: Neuropsychiatr Genet 153B:67-78
11. Crandall CJ, Miller-Martinez D, Greendale GA, Binkley N, Seeman TE, Karlamangla AS. 2012. Socioeconomic status, race, and bone turnover in the Midlife in the US Study. Osteoporo Int 23:1503-1512
12. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. 2009. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
13. Dempster DW. 2011. Osteoporosis and the burden of osteoporois-related fractures. Am J Managed Care 17:S164-S169
14. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE. 2007. Use of antidepressants and rates of hip bone loss in older women: The study of osteoporotic fractures. Arch Intern Med 167:1240-1245
15. Dombrovski AY, Mulsant BH, Ferrell RE, Lotrich FE, Rosen JI, Wallace M, et al. 2010. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 25:37-45
16. First MB, Spitzer RL, Gibbon M. 1996. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version: Administration Booklet. Washington, DC: NIH
17. Frodl T, Zill P, Baghai T, Schule C, Rupprecht R, Zetzsche T, et al. 2008. Reduced hippocampal volumes associated with the long variant of the tri-And diallelic serotonin transporter polymorphism in major depression. Am J Med Genet B Neuropsychiatr Genet 147B:1003-1007
18. Gelernter J, Kranzler HR, Cubells JF. 1997. Serotonin transporter protein (SLC6A4) allele haplotype frequencies and linkage disequilibrium in African-And European-American and Japanese populations in alcohol-dependent subjects. Hum Genet 101:243-246
19. Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, et al. 2006. Serotonin and fl uoxetine modulate bone cell function in vitro. J Cell Biochem 98:139-151
20. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, et al. 2007. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Inter Med 167:1246-1251
21. Haney EM, Warden SJ, Bliziotes MM 2010. Effects of selective serotonin reuptake inhibitors on bone health in adults: Time for recommendations about screening, prevention and management?. Bone 46:13-17
22. Hodge JM, Wang Y, Berk M, Collier FM, Fernandes TJ, Constable MJ, et al. 2012. Selective seritonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry pii: S0006-3223(12)00982-1
23. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. 2006. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78:815-826
24. Joel I, Begley AE, Mulsant BH, Lenze EJ, Dew MA, Blumberger D, et al. 2014. Dynamic prediction of treat ment response in late-life depression. Am J Geriatr Psychiatry 22:167-176
25. Karsenty G, Oury F. 2010. The central reguation of bone mass, the fi rst link betwen bone remodeling and energy metabolism. J Clin Endocrinol Metab 95:4795-4801
26. Karsenty G, Yadav VK. 2011. Regulation of bone mass by serotonin: Molecular biology and therapeutic implications. Annu Rev Med 62:323-331
27. Kenna GA, Rodger-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, et al. 2012. Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: Review of psychopathology and pharmacotherapy. Pharmacogen Personal Med 5:19-35
28. Lenze EJ, Dixon D, Nowotny P, Lotrich FE, Dore PM, Pollock BG, et al. 2013. Escitalopram reduces attentional performance in anxious older adults with high-expressing genetic variants at serotonin 2A and 1B receptors. Int J Neuropsychopharmacol 16:279-288
29. Lewiecki EM, 2010. Benefi ts and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis. Curr Osteoporos Rep 8:15-22
30. Looker AC, Borrund LG, Dawson-Hughes B, Shepherd JA, Wright NC. 2012. Osteoporosis or low bone mineral mass at the femur neck or lumbar spine in older adults: United States, 2005-2008, In NCHS Data Brief No. 93. Hyattsville, MD: NCHS
31. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry: J Mental Sci 134:382-389
32. Nishizawa Y, Nakamura T, Ohta H, KushiDa K, Gorai I, Shiraki M, et al Committee on the Guidelines for the use of Biochemical Markers of Bone Turnover in Osteoporosis, J.O.S. 2005. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Mineral Metab 23:97-104
33. O'Donnell JM, Shelton RC. 2011. Drug therapy of depression and anxiety disorders. In:Brunton LL, Knollmann BC, editors. Goodman & Gillman " s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill
34. Olfson M, Marcus SC. 2009. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66:848-856
35. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D. 2007. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188-194
36. Shea MLO, Garfi eld LD, Teitelbaum S, Civitelli R, Mulsant BH, Reynolds CF, et al. 2013. Serotonin-norepinepherine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resporption. Osteoporos Int 24:1741-1749
37. Steiger H, Richardson J, Joober R, Gauvin L, Israel M, Bruce KR, et al. 2007. The 5HTTLPR polymorphism, prior maltreatment and dramatic-erratic personality manifestations in women with bulimic syndromes. J Psychiatry Neurosci 32:354-362
38. Thakur GA, Grizenko N, Sengupta SM, Schmitz N, Joober R. 2010. The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD. BMC Psychiatry 10:50
39. Wankerl M, Zyriax BC, Bondy B, Hinkelmann K, Windler E, Otte C. 2010. Serotonin transporter gene-linked polymorphic region (5-HTTLPR) and diurnal cortisol: A sex by genotype interaction. Biol Psychol 85:344-346
40. Warden SJ, Nelson IR, Fuchs RK, Bliziotes MM, Turner CH. 2008. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen defi-ciency. Menopause 15:1176-1183
41. Warden SJ, Hassett SM, Bond JL, Rydberg J, Grogg JD, Hilles EL, et al. 2010a. Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels. Bone 46:985-992
42. Warden SJ, Robling AG, Haney EM, Turner CH, Bliziotes MM. 2010b. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 46:4-12
43. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL. 2006. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 11:224-226
44. Westbroek I, van der Plas A, De Rooij KE, Klein-Nulend J, Nijweide PJ. 2001. Expression of serotonin receptors in bone. J Biol Chem 276:28961-28968
45. Westbroek I, Waarsing JH, van Leeuwen JP, Waldum H, Reseland JE, Weinans H, et al. 2007. Long-Term fl uoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 101:360-368
46. Yadav VK, Ducy P. 2010. Lrp5 and bone formation: A serotonindependent pathway. Ann NY Acad Sci 1192:103-109
47. Yadav VK, Ryu JH, SuDa N, Tanaka KF, Gingrich JA, Schutz G, et al. 2008. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837.